Patient reported outcomes after minimally invasive retroperitoneal pancreatic necrosectomy to treat acute pancreatitis – an exploratory study.

Category: Bunion Introduction/Purpose: The aim of this study was to explore the 2 year results of third generation (using screw fixation) Minimally Invasive Chevron and Akin osteotomies (MICA) for hallux valgus correction. There is a paucity of published data regarding the outcomes of this relatively new technique. We present the largest series in the literature, using three separate validated patient-reported outcome measures (EQ-5DL, VAS Pain and Manchester Oxford Foot Questionnaire (MOXFQ), for this time point. Methods: A single surgeon case series of patients with hallux valgus underwent primary third generation minimally invasive chevron and akin osteotomies for hallux valgus correction. Between August 2015 and January 2018, 290 MICAs were performed in 203 patients that were eligible for 2 year follow up. Baseline and 2 year post-operative patient reported outcomes were collected for 164 feet in 130 patients (124 females; 6 males). Paired t-tests were used to determine the statistical significance of the difference between pre- and post-operative scores. Results: The mean age was 56.6 (range 29.5-81.0, standard deviation (s.d.) 10.9). At two year follow up, mean MOXFQ scores improved for each domain: Pain; baseline 40.6 (range 0-100, s.d. 22.8), reduced to 11.3 (range 0-75, s.d. 16.0, p<0.001); Walking; 36.0 (range 0-100, s.d. 25.9) reduced to 8.2 (range 0-75.0, s.d. 16.0, p<0.001); Social interaction; 46.7 (range 0-100, s.d. 24.3), reduced to 7.7 (range 0-75.0, s.d. 13.9, p<0.001). Mean VAS Pain score improved from 30.4 (range 0.0-90.0, s.d. 23.6) to 9.4 (range 0.00-70.0, s.d. 15.6, p<0.001). Mean EQ-5D index score improved from 0.750 (range 0.066-1.000, s.d. 0.148) to 0.892 (range 0.410-1.000, s.d. 0.135, p<0.001). Mean EQ-5D VAS score did not significantly improve from 81.9 (range 0-100, s.d. 17.1) to 83.0 (range 0-100, s.d. 18.0, p=0.559). Conclusion: This is the largest prospective case series of short-term patient reported outcomes using a validated assessment method for hallux valgus, following third generation MICA to date. These data show that this technique is effective at improving foot and ankle specific patient reported outcomes at 2 years. This cohort is being followed over the longer term.

Download Full-text

A feasibility exploratory study of a novel modality of using patient-reported outcomes (PROsEXPLOR) in the real world

Tumori Journal ◽

10.1177/0300891620923745 ◽

2020 ◽

Vol 106 (6) ◽

pp. 464-470

Author(s):

Federica Grosso ◽

Stefania Crivellari ◽

Marinella Bertolotti ◽

Michela Lia ◽

Antonina De Angelis ◽

...

Keyword(s):

Emergency Department ◽

Clinical Practice ◽

Adverse Events ◽

Exploratory Study ◽

Patient Reported Outcomes ◽

Routine Clinical Practice ◽

Satisfaction Survey ◽

Home Therapy ◽

Patient Reported ◽

Hospital Visits

Introduction: Patient-reported outcomes (PROs) can help clinicians better evaluate chemotherapy and immunotherapy toxicity based on patient perspectives. In this exploratory study, we tested a simplified PRO questionnaire (sPQ) in routine clinical practice and patient satisfaction with this tool. Methods: We included 16 items related to the main toxicities of chemotherapy and immunotherapy to be filled in by patients. A baseline sPQ was completed by patients before starting treatment and then in the interval between courses for a total of 4 sPQs. Patients communicated the results to a data manager, who alerted the referral oncologist in case of replies differing from the basal or previous sPQ. According to the severity of symptoms, the patient was then referred to the team nurse, the general practitioner, or another specialist. A satisfaction survey was also completed. Results: In a 3-month interval, 27 patients were enrolled. Fatigue and nausea were the most frequent symptoms reported as worsening during treatment. The oncologist was involved in the management of adverse events in 4 cases, home therapy variations were recommended by the dedicated nurse in 14 cases, additional visits were performed in 6 patients, and 1 patient was admitted to the oncology ward. None of the patients had unplanned visits to the emergency department or to the hospital. The sPQ was judged to be simple, useful, and satisfactory. Conclusions: Using sPQs in routine clinical practice was feasible and well-accepted by patients. PROs allowed us to recognize and promptly manage adverse events, reducing unplanned emergency department or hospital visits to zero.

Download Full-text

82: Patient-Reported Outcomes after the Minimally Invasive Approach to Lung Transplantation

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2009.11.090 ◽

2010 ◽

Vol 29 (2) ◽

pp. S33-S33

Author(s):

A. DeVito Dabbs ◽

M.A. Dew ◽

D. Zaldonis ◽

J. Aubrecht ◽

M.M. Crespo ◽

...

Keyword(s):

Minimally Invasive ◽

Lung Transplantation ◽

Patient Reported Outcomes ◽

Minimally Invasive Approach ◽

Invasive Approach ◽

Patient Reported

Download Full-text

Preoperative Mental Health is not Predictive of Patient-reported Outcomes Following a Minimally Invasive Lumbar Discectomy

Clinical Spine Surgery ◽

10.1097/bsd.0000000000000466 ◽

2017 ◽

Vol 30 (10) ◽

pp. E1388-E1391 ◽

Cited By ~ 3

Author(s):

Benjamin C. Mayo ◽

Dustin H. Massel ◽

Daniel D. Bohl ◽

William W. Long ◽

Krishna D. Modi ◽

...

Keyword(s):

Mental Health ◽

Minimally Invasive ◽

Patient Reported Outcomes ◽

Lumbar Discectomy ◽

Patient Reported

Download Full-text

Characteristics and patient-reported outcomes associated with dropout in severely affected oncological patients: an exploratory study

BMC Medical Research Methodology ◽

10.1186/s12874-021-01259-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Pimrapat Gebert ◽

Daniel Schindel ◽

Johann Frick ◽

Liane Schenk ◽

Ulrike Grittner

Keyword(s):

Quality Of Life ◽

Social Support ◽

Exploratory Study ◽

Patient Reported Outcomes ◽

Drop Out ◽

Health Related Quality ◽

Patient Reported ◽

Related Quality ◽

Health Related

Abstract Background Patient-reported outcome measures (PROMs) are commonly-used surrogates for clinical outcomes in cancer research. When researching severe diseases such as cancer, it is difficult to avoid the problem of incomplete questionnaires from drop-outs or missing data from patients who pass away during the observation period. The aim of this exploratory study was to explore patient characteristics and the patient-reported outcomes associated with the time-to-dropout. Methods In an Oncological Social Care Project (OSCAR) study, the condition of the participants was assessed four times within 12 months (t0: baseline, t1: 3 months, t2: 6 months, and t3: 12 months) by validated PROMs. We performed competing-risk regressions based on Fine and Gray’s proportional sub-distribution hazards model for exploring factors associated with time-to-dropout. Death was considered a competing risk. Results Three hundred sixty-two participants were analyzed in the study. 193 (53.3%) completed a follow-up after 12 months, 67 (18.5%) patients dropped out, and 102 patients (28.2%) died during the study period. Poor subjective social support was related to a higher risk of drop-out (SHR = 2.10; 95%CI: 1.01–4.35). Lower values in health-related quality of life were related to drop-out and death. The sub-scales global health status/QoL, role functioning, physical functioning, and fatigue symptom in the EORTC QLQ-C30 were key characteristics of early drop-out. Conclusion Severely affected cancer patients with poor social support and poor quality of life seem more likely to drop out of studies than patients with higher levels of social support and a better quality of life. This should be considered when planning studies to assess advanced cancer patients. Methods of close continued monitoring should be actively used when patient experiences a substantial deterioration in their health-related quality of life and symptoms during the study. Results for such studies have to be interpreted with caution in light of specific drop-out mechanisms. Trial registration OSCAR study was registered to the German Clinical Trials Register (DRKS-ID: DRKS00013640). Registered 29 December 2017.

Download Full-text